Clarity Around Medication Types and Limitations Minor issues Belle clearly states that compounded medications are not FDA approved, which is the disclosure I want to see
Additionally, per publicly available FDA and manufacturer announcements, orforglipron (Eli Lilly's Foundayo, a non-peptide oral GLP-1 receptor agonist) received FDA approval on April 1, 2026 for chronic weight management
Of particular interest is silymarin, a derivation of the milk thistle plant
Ten suplement wspiera naturalne procesy spalania tuszczu, dostarcza dodatkowej energii i zwiksza wytrzymao
So while obesity is linked to worse outcomes in patients with breast cancer, weight loss may not be the only way that GLP-1 drugs are lowering risk
5lbs down and minimal side effects besides surprised appetite Im into my first month